D. Marchion

发表

In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival

R. Wenham, J. Gonzalez-Bosquet, N. Chen, 2012, British Journal of Cancer.

Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/ii Trial of Valproic Acid and Epirubicin/fec Cancer Therapy: Clinical

P. Munster, A. Daud, E. Biçaku, 2022 .

Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.

J. Lancaster, R. Wenham, Y. Xiong, 2016, Gynecologic oncology.

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

P. Munster, D. Sullivan, A. Daud, 2009, Clinical Cancer Research.

Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.

M. Fishman, J. Lee, A. Daud, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker

P. Munster, D. Sullivan, A. Daud, 2009, British Journal of Cancer.

ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression

D. Munn, S. Mehrotra, D. Marchion, 2019, Nature Communications.

The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.

J. Lancaster, R. Wenham, J. Gonzalez-Bosquet, 2012, International journal of oncology.

Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes

R. Wenham, J. Lancaster, D. Marchion, 2021, bioRxiv.

Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes.

J. Lancaster, R. Wenham, D. Marchion, 2021, PloS one.

ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy.

R. Wenham, C. Cubitt, Y. Xiong, 2017, Cancer control : journal of the Moffitt Cancer Center.

HDAC2 regulates chromatin plasticity and enhances DNA vulnerability

P. Munster, E. Biçaku, D. Marchion, 2009, Molecular Cancer Therapeutics.

Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy

P. Munster, E. Biçaku, D. Marchion, 2008 .

Phase I/II trial combining the HDAC inhibitor, valproic acid (VPA) and FEC100 (5-fluorouracil, epirubicin and cyclophosphamide) in locally advanced/metastatic breast cancer

P. Munster, A. Daud, E. Biçaku, 2007 .

Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.

P. Munster, D. Sullivan, A. Daud, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.

N. Rosen, D. Marchion, A. Basso, 2002, Cancer research.

Generation of antiserum to specific epitopes

W. Shafer, D. Marchion, R. C. Judd, 1996, Molecular biotechnology.

Recombinant vaccines to prevent gonorrhea| Maltose binding protein/gonococcal antigenic peptide fusion proteins

D. Marchion, 1996 .

Phase I trial of a sequence-specific combination of the HDAC inhibitor, vorinostat (SAHA) followed by doxorubicin in advanced solid tumor malignancies

P. Munster, A. Daud, M. Egorin, 2007 .

Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation

K. Tsai, P. Gunaratne, K. Rajapakshe, 2020, Nature Communications.

BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells

D. Marchion, P. Bobrowicz, D. Gabrilovich, 2020, Science.

ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression

D. Munn, S. Mehrotra, D. Marchion, 2019, Nature Communications.

Synergistic Interaction between Histone Deacetylase and Topoisomerase II Inhibitors Is Mediated through Topoisomerase IIβ

P. Munster, D. Sullivan, A. Daud, 2005, Clinical Cancer Research.

IgA transcytosis and antigen recognition govern ovarian cancer immunity

Chandler D. Gatenbee, R. Wenham, D. Marchion, 2021, Nature.

BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival

S. Eschrich, A. Berchuck, J. Lancaster, 2011, Clinical Cancer Research.

Molecular determinants for lymph node metastasis in clinically early-stage endometrial cancer.

J. Lancaster, R. Wenham, J. Gonzalez-Bosquet, 2016, Oncology letters.

Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer

Q. Mo, Jingsong Zhang, E. Siegel, 2023, International journal of molecular sciences.

Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells.

Chandler D. Gatenbee, Sandhya Prabhakaran, R. Wenham, 2022, Cancer cell.

Development of histone deacetylase inhibitors for cancer treatment

D. Marchion, P. Münster, 2007, Expert review of anticancer therapy.

BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin

J. Lancaster, R. Wenham, J. Gonzalez-Bosquet, 2012, Journal of gynecologic oncology.

Predictive Biomarkers and Personalized Medicine BAD Phosphorylation Determines Ovarian Cancer Chemosensitivity and Patient Survival

S. Eschrich, A. Berchuck, J. Lancaster, 2011 .

Category : Predictive Biomarkers and Personalized Medicine BAD phosphorylation determines ovarian cancer chemo-sensitivity and patient survival

S. Eschrich, A. Berchuck, J. Lancaster, 2011 .

Activation of connective tissue cells in vital pericardium relevance to the behavior of vital autologous pericardial implants in cardiovascular surgeries

D. Marchion, 2001 .

BAD-mediated apoptotic pathway is associated with human cancer development

J. Lancaster, R. Wenham, E. Biçaku, 2015, International journal of molecular medicine.

Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel

T. Sellers, J. Lancaster, R. Wenham, 2013, Oncology reports.

A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth

J. Lancaster, R. Wenham, J. Gonzalez-Bosquet, 2013, Oncology reports.

Gene expression data reveal common pathways that characterize the unifocal nature of ovarian cancer.

J. Lancaster, R. Wenham, J. Gonzalez-Bosquet, 2013, American journal of obstetrics and gynecology.

Expression of the BAD pathway is a marker of triple-negative status and poor outcome

J. Lancaster, H. Park, M. Pena, 2019, Scientific Reports.

The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.

J. Lancaster, R. Wenham, J. Gonzalez-Bosquet, 2012, Gynecologic oncology.

ABCG2 expression, function, and promoter methylation in human multiple myeloma.

M. Schell, W. Dalton, P. Munster, 2006, Blood.

Sequence‐specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid

P. Munster, D. Sullivan, A. Daud, 2004, Journal of cellular biochemistry.

Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.

Peter Washausen, D. Sullivan, L. Hazlehurst, 2009, Cancer research.

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins.

P. Munster, D. Sullivan, A. Daud, 2005, Cancer research.

Behavior of vital and killed autologous pericardium in the descending aorta of sheep.

C. Duran, D. Marchion, S. Choo, 1999, The Journal of thoracic and cardiovascular surgery.

Cellular expression of PCNA and procollagen in vital and ethanol-treated autologous pericardial implants in sheep.

C. Duran, D. Marchion, D. Cheung, 2003, The Journal of heart valve disease.

Characterizing the Efficacy of Fermented Wheat Germ Extract Against Ovarian Cancer and Defining the Genomic Basis of Its Activity

J. Lancaster, R. Wenham, J. Gonzalez-Bosquet, 2012, International Journal of Gynecologic Cancer.

Addition of a histone deacetylase inhibitor redirects tamoxifen-treated breast cancer cells into apoptosis, which is opposed by the induction of autophagy

E. Biçaku, D. Marchion, K. Thurn, 2011, Breast Cancer Research and Treatment.

Prognostic and predictive factors in human breast cancer

P. Munster, D. Marchion, S. Maunglay, 2007 .

IN HUMAN BREAST CANCER

Pamela N. Munster, P. Munster, D. Marchion, 2007 .

Biologic Mechanisms Linked to Prognosis in Ovarian Cancer that May Be Affected by Aging

Y. Xiong, D. Marchion, H. Chon, 2019, Journal of Cancer.

Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling.

E. Biçaku, D. Marchion, P. Münster, 2008, Cancer research.

In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates

P. Munster, D. Sullivan, A. Daud, 2005, Molecular Cancer Therapeutics.

Metabolic vulnerabilities in endometrial cancer.

J. Lancaster, K. Ravichandran, K. Hoehn, 2014, Cancer research.

Sensitivity of ovarian cancer cells to acetaminophen reveals biological pathways that affect patient survival.

J. Lancaster, R. Wenham, L. Havrilesky, 2016, Molecular and clinical oncology.

Gene expression profiling of 389 endometrioid endometrial carcinomas reveals 4 distinct molecular subtypes

Y. Xiong, D. Marchion, H. Chon, 2016 .

Unique molecular portraits of ovarian cancer: Implications for prognostics and targeted therapeutics

J. Lancaster, Y. Xiong, D. Marchion, 2015 .

An in vitro model of pericardial tissue healing.

C. Duran, D. Marchion, D. Cheung, 2003, Biomaterials.

The Chinese herb polyphyllin D sensitizes ovarian cancer cells to cisplatin-induced growth arrest

J. Lancaster, R. Wenham, Y. Xiong, 2015, Journal of Cancer Research and Clinical Oncology.

Analysis of chemotherapeutic response in ovarian cancers using publicly available high-throughput data.

S. Chanock, J. Lancaster, D. Marchion, 2014, Cancer research.

Phase I trial of a sequence-specific combination of the HDAC inhibitor, valproic acid (VPA), and the topoisomerase II inhibitor, epirubicin, in advanced solid tumors: Clinical results and correlative studies.

P. Stauffer, P. Munster, D. Sullivan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer

U. Rix, D. Marchion, H. Lawrence, 2022, The Journal of biological chemistry.

Prediction of Optimal Cytoreductive Surgery of Serous Ovarian Cancer With Gene Expression Data

J. Lancaster, R. Wenham, J. Gonzalez-Bosquet, 2015, International Journal of Gynecologic Cancer.

A new method for the preservation of aortic valve homografts.

Y. Shomura, C. Duran, D. Marchion, 2001, The Journal of heart valve disease.

Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells.

Chandler D. Gatenbee, Sandhya Prabhakaran, R. Wenham, 2022, Cancer cell.

Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.

J. Lancaster, R. Wenham, Y. Xiong, 2013, Gynecologic oncology.

Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC

P. Munster, E. Biçaku, D. Marchion, 2009, Clinical Cancer Research.

Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes

R. Wenham, D. Marchion, T. Gheit, 2023, PloS one.